Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis

The Lancet

Volumn 387, Issue 10022, 2016, Pages 957-967

  Ettehad, Dena ^a   Emdin, Connor A ^a   Kiran, Amit ^a   Anderson, Simon G ^a,b   Callender, Thomas ^a,c   Emberson, Jonathan ^a   Chalmers, John ^d   Rodgers, Anthony ^d   Rahimi, Kazem ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; MORTALITY;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION;

EID: 84960094179     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01225-8     Document Type: Article

References (70)

1. WHO A global brief on hypertension 2013 World Health Organization Geneva
2. S Lewington, R Clarke, N Qizilbash, R Peto, C Collins Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 2002 1903 1913
3. CMM Lawes, A Rodgers, DA Bennett et al. Blood pressure and cardiovascular disease in the Asia Pacific region J Hypertens 21 2003 707 716
4. E Rapsomaniki, A Timmis, J George et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people Lancet 383 2014 1899 1911
5. R Collins, R Peto, S MacMahon et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context Lancet 335 1990 827 838
6. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
7. J Staessen, R Fagard, L Thijs et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 350 1997 757 764
8. NS Beckett, R Peters, AE Fletcher et al. Treatment of hypertension in patients 80 years of age or older N Engl J Med 358 2008 1887 1898
9. A Patel, S MacMahon, J Chalmers et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial Lancet 370 2007 829 840
10. PROGRESS Collaborative Group Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
11. S Yusuf, P Sleight, J Pogue, J Bosch, R Davies, G Dagenais Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients N Engl J Med 342 2000 145 153
12. JTJ Wright, JD Williamson, PK Whelton et al. A randomized trial of intensive versus standard blood-pressure control N Engl J Med 373 2015 2103 2116
13. C Emdin, K Rahimi, B Neal, T Callender, V Perkovic, A Patel Blood pressure lowering in type 2 diabetes JAMA 313 2015 603 615
14. P James, S Oparil, B Carter et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
15. JT Wright Jr, LJ Fine, DT Lackland, G Ogedegbe, CR Dennison Himmelfarb Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view Ann Intern Med 160 2014 499 503
16. MR Law, JK Morris, NJ Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
17. G Mancia, R Fagard, K Narkiewicz, J Redon, A Zanchetti, M Bohm 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 2013 2159 2219
18. NICE The clinical management of primary hypertension in adults: Clinical guideline 127 2011 National Institute for Health and Care Excellence London
19. A Liberati, DG Altman, J Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions PLoS Med 6 2009 e1000100
20. LL Kjaergard, J Villumsen, C Gluud Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses Ann Intern Med 135 2001 982 989
21. World Health Organization - International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments J Hypertens 16 1998 127 137
22. I Annesi, T Moreau, J Lellouch Efficiency of the logistic regression and Cox proportional hazards models in longitudinal studies Stat Med 8 1989 1515 1521
23. JP Higgins, S Green Cochrane Handbook for Systematic Reviews of Interventions 2008 John Wiley & Sons Chichester i xxi
24. JPT Higgins, SG Thompson, JJ Deeks, DG Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
25. C Baigent, R Peto, R Gray, S Parish, R Collins Large-scale randomized evidence: trials and meta-analyses of trials D Warrell T Cox J Firth Oxford textbook of medicine 5th edn. 2010 Oxford University Press New York
26. SE Nissen, EM Tuzcu, P Libby et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: A randomized controlled trial JAMA 292 2004 2217 2226
27. L Hansson, A Zanchetti, SG Carruthers et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
28. EJ Lewis, LG Hunsicker, WR Clarke et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
29. Medical Research Council Working Party MRC trial of treatment of mild hypertension: Principal results BMJ 291 1985 97 104
30. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: Principal results BMJ 304 1992 405 412
31. V Chaturvedi, A Patel, J Chalmers et al. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease Eur Heart J 24 2003 475 484
32. P Ruggenenti, A Fassi, AP Ilieva et al. Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951
33. PA Meredith, J Östergren, I Anand et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program J Am Coll Cardiol 52 2008 2000 2007
34. JL Rouleau, EB Roecker, M Tendera et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure the carvedilol prospective randomized cumulative survival (COPERNICUS) study J Am Coll Cardiol 43 2004 1423 1429
35. IS Anand, SW Tam, TS Rector et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the african-american heart failure trial J Am Coll Cardiol 49 2007 32 39
36. JT Wright, G Bakris, T Greene et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial JAMA 288 2002 2421 2431
37. RO Estacio, BW Jeffers, WR Hiatt, SL Biggerstaff, N Gifford, RW Schrier The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 1998 645 652
38. RW Schrier, RO Estacio, PS Mehler, WR Hiatt Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial Nat Clin Pract Nephrol 3 2007 428 438
39. RW Schrier, RO Estacio, A Esler, P Mehler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 2002 1086 1097
40. K Asayama, T Ohkubo, H Metoki et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure Hypertens Res 35 2012 1102 1110
41. R Holman, R Turner, I Stratton et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 BMJ 317 1998 713 720
42. R Turner, R Holman, I Stratton et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
43. J McMurray, S Solomon, K Pieper et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: An analysis of the valsartan in acute myocardial infarction trial (VALIANT) J Am Coll Cardiol 47 2006 726 733
44. S Yusuf, H Diener, RL Sacco et al. Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
45. L Hansson, LH Lindholm, L Niskanen et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
46. L Wilhemsen, G Berglund, D Elmfeldt et al. Beta-blockers versus diuretics in hypertensive men: Main results from the HAPPHY trial J Hypertens 5 1987 561 572
47. K Kanamasa, A Kimura, M Miyataka, T Takenaka, K Ishikawa Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem Cancer 85 1999 1369 1374
48. T Levine, P Bernink, A Caspi et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study Circulation 101 2000 758 765
49. National Intervention Cooperative Study in Elderly Hypertensives Study Group Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives Hypertension 34 1999 1129 1133
50. H Ogawa, S Kim-Mitsuyama, K Matsui, T Jinnouchi, H Jinnouchi, K Arakawa Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients Am J Med 125 2012 981 990
51. A Helgeland Treatment of mild hypertension: A five year controlled drug trial. The Oslo study Am J Med 69 1980 725 732
52. L Gong, W Zhang, Y Zhu et al. Shanghai trial of nifedipine in the elderly (STONE) J Hypertens 14 1996 1237 1245
53. L Liu, J Wang, L Gong, G Liu, J Staessen Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension J Hypertens 16 1998 1823 1829
54. JG Wang, J Staessen, L Gong, L Liu Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group Arch Intern Med 160 2000 211 220
55. T Ogihara, H Matsuoka, H Rakugi Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan Geriatr Gerontol Int 11 2011 414 421
56. X Xie, E Atkins, J Lv et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: A systematic review and meta-analysis Lancet 2015 published online Nov 7. http://dx.doi.org/10.1016/S0140-6736(15)00805-3
57. WC Cushman, GW Evans, RP Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
58. E Di Angelantonio, S Kaptoge, D Wormser et al. Association of cardiometabolic multimorbidity with mortality JAMA 314 2015 52 60
59. H-H Parving, BM Brenner, JJ McMurray et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 2012 2204 2213
60. B Neal, S MacMahon, N Chapman Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: Results of prospectively designed overviews of randomised trials Lancet 356 2000 1955 1964
61. C Thomopoulos, G Parati, A Zanchetti Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses J Hypertens 33 2015 195 211
62. K Jamerson, MA Weber, GL Bakris et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
63. J Sundström, H Arima, R Jackson et al. Effects of blood pressure reduction in mild hypertension Ann Intern Med 162 2015 184 191
64. K Rahimi, S MacMahon Blood pressure management in the 21st century: Maximizing gains and minimizing waste Circulation 128 2013 2283 2285
65. C Thomopoulos, G Parati, A Zanchetti Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials J Hypertens 32 2014 2285 2295
66. F Turnbull, B Neal, C Algert, J Chalmers, M Woodward, S MacMahon Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
67. T Ninomiya, V Perkovic, F Turnbull et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-analysis of randomised controlled trials BMJ 347 2013 f5680
68. J Coresh, B Astor, T Greene, G Eknoyan, A Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
69. S Chadban, E Briganti, P Kerr et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study J Am Soc Nephrol 14 7 Suppl 2 2003 S131 S138
70. V Perkovic, A Cass, A Patel et al. High prevalence of chronic kidney disease in Thailand Kidney Int 73 2008 473 479